Company Filing History:
2 out of 356 
2 out of 230 
1 out of 263 Years Active: 2014-2025
Title: Alexander Joseph Reif: Pioneering Innovations in Pharmaceutical Compounds
Introduction
Alexander Joseph Reif, an accomplished inventor based in Collegeville, PA, holds a remarkable portfolio of four patents. His work primarily focuses on developing innovative pharmaceutical compounds aimed at treating various medical disorders, thereby contributing significantly to medical science.
Latest Patents
Among his latest patents, Reif has made notable strides with compounds such as “Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors.” This invention relates to compounds designed to treat autoimmune, autoinflammatory, or immune-mediated conditions, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and lupus nephritis.
Another significant patent is for “Substituted pyridines as inhibitors of DNMT1.” This invention focuses on substituted pyridine derivatives that are selective inhibitors of DNMT1. These compounds can potentially treat cancer, pre-cancerous syndromes, and various hemoglobinopathy disorders, including sickle cell disease and beta thalassemia.
Career Highlights
Throughout his career, Reif has been associated with prestigious organizations such as GlaxoSmithKline and GlaxoSmithKline Intellectual Property Development Limited. His extensive experience in the pharmaceutical industry has equipped him with valuable insights and expertise in the field of drug development and patenting.
Collaborations
During his professional journey, Alexander Joseph Reif has collaborated with notable colleagues like Nicholas D Adams and Kenneth Wiggall. These partnerships have undoubtedly facilitated the advancement of his innovative ideas and contributions to the pharmaceutical realm.
Conclusion
In summary, Alexander Joseph Reif stands out as a significant inventor in pharmaceuticals, holding four patents that showcase his innovative spirit and dedication to improving healthcare. His recent work on cGAS inhibitors and DNMT1 inhibitors holds promise for treating complex medical conditions, demonstrating the impactful potential of his inventions.